5-Amino-1MQ: What the Research Actually Shows
A small-molecule NNMT inhibitor with a clear, well-documented mechanism and a growing body of preclinical evidence on fat mass, muscle aging, and, as of a 2025-2026 study, kidney-tubule aging, now including the first human cell data for this compound, though still zero completed human trials of 5-Amino-1MQ itself as of today. It is grouped with peptide therapies on this site by clinical use, not by chemistry, and this guide keeps that distinction, and the evidence gap, plainly stated.
A Small Molecule That Blocks an Enzyme Competing for Your NAD+ Supply
5-Amino-1MQ is a small-molecule quinolinium compound, not a peptide, despite being offered and discussed alongside peptide therapies. It's grouped that way on this site because of how it's used clinically, not because of its chemical structure. Its target is nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide, the same nicotinamide your cells otherwise use to build NAD+, into 1-methylnicotinamide (1-MNA), using S-adenosyl-L-methionine (SAM) as the methyl donor. Every molecule of nicotinamide that NNMT diverts into 1-MNA is a molecule that can no longer enter the NAD+ salvage pathway, and every methylation event also consumes SAM, the same methyl donor pool cells rely on for DNA and histone methylation and dozens of other reactions. Inhibit NNMT, and less nicotinamide gets shunted away, leaving more available for NAD+ synthesis, while also sparing SAM for other methylation work. That is the entire mechanistic case for 5-Amino-1MQ, and it is a real, biochemically coherent one. It is not, on its own, evidence that giving the compound to a person raises their NAD+ or produces a clinical benefit.
Evidence Summary
Mouse Data, Human-Observational Correlations, and a First Look in Human Kidney Cells
The Foundational Finding: Validating NNMT as a Target, Before Any Drug Existed
Kraus D, Yang Q, Kong D, et al. "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature. 2014;508(7495):258-262. doi: 10.1038/nature13198. PMID: 24717514. Before 5-Amino-1MQ or any small-molecule NNMT inhibitor existed, this Nature paper asked a more basic question: if NNMT is removed directly, using antisense oligonucleotides to knock the gene down in the liver and fat of mice, does that protect against obesity? It did. Mice with NNMT knocked down were protected against both diet-induced and genetically driven obesity, showed improved insulin sensitivity and higher energy expenditure, and lost fat without eating less, through a metabolic cycle that burns additional calories via polyamine metabolism, the same NAD+/SAM biology this entire guide is built around. This is genetic proof that the target itself matters, not a test of the drug: it doesn't predict what a small molecule like 5-Amino-1MQ will do in a person, but it's the reason a small-molecule NNMT inhibitor was worth developing in the first place, and it means this mechanism was validated at the whole-animal level years before the compound existed.
Mouse Study (Genetic Knockdown, Diet-Induced and Genetic Obesity Models) · Endpoint: Body Weight, Energy Expenditure, and Insulin Sensitivity, Target Validation Only, Not a Test of the DrugDiscovery and Mechanism: NNMT Inhibition Reverses Diet-Induced Obesity in Mice
Neelakantan H, Vance V, Wetzel MD, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochemical Pharmacology. 2018;147:141-152. doi: 10.1016/j.bcp.2017.11.007. PMID: 29155147. This is the original discovery paper. In diet-induced obese male mice (16 weeks on a 45%-fat diet), 11 days of 5-Amino-1MQ (20 mg/kg subcutaneously, three times daily) produced a 5.1% body weight loss versus a 1.4% gain in controls, a roughly 35% reduction in epididymal fat pad mass (p<0.001), and a greater than 30% reduction in adipocyte size (p<0.05), with no change in food intake, meaning the effect wasn't simply appetite suppression. Plasma cholesterol fell by about 30% (p<0.05). In parallel cell culture work, NNMT inhibition raised intracellular NAD+ by roughly 1.2 to 1.6-fold and increased SAM levels, without changing nicotinamide or SAH levels, directly confirming the proposed mechanism at the cellular level. The authors themselves note the treatment period was short (11 days) and that the transport mechanism getting the compound into cells still needed further study.
Mouse Study (Diet-Induced Obesity Model) + In Vitro Adipocyte Work · Endpoint: Body Weight, Fat Mass, Adipocyte Size, and Intracellular NAD+/SAM at 11 Days, Not a Human OutcomeThe Human Evidence That Exists: NNMT and Insulin Resistance, Observed, Not Intervened On
Kannt A, Pfenninger A, Teichert L, et al. "Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance." Diabetologia. 2015;58(4):799-808. doi: 10.1007/s00125-014-3490-7. Across three independent human cohorts (199 patients undergoing abdominal surgery, 60 patients completing a 12-week exercise program, and 55 patients undergoing bariatric surgery), this study found that people with type 2 diabetes had roughly twice the NNMT expression in their white adipose tissue as those without, and that both plasma 1-MNA and adipose NNMT mRNA correlated with insulin resistance measured by hyperinsulinemic-euglycemic clamp (adipose NNMT mRNA versus glucose infusion rate, r=0.64, p<0.001 in one cohort and r=0.78, p<0.001 in a second). Exercise and bariatric surgery both significantly lowered adipose NNMT expression (p<0.001). This is genuine human evidence that NNMT activity tracks with insulin resistance, and that interventions which improve insulin sensitivity happen to lower NNMT along the way. It is not evidence that inhibiting NNMT with a drug improves insulin resistance in people; no one in this study received an NNMT inhibitor.
Human Observational Study, Three Cohorts (n=199, n=60, n=55) · Endpoint: Correlation Between NNMT Expression/1-MNA and Insulin Resistance, Observational, Not InterventionalAged Skeletal Muscle: Reactivating Senescent Muscle Stem Cells in Mice
Neelakantan H, Brightwell CR, Graber TG, et al. "Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle." Biochemical Pharmacology. 2019;163:481-492. doi: 10.1016/j.bcp.2019.02.008. PMID: 30753815. In aged mice, 5-Amino-1MQ treatment increased proliferation of muscle stem cells (satellite cells) that had become senescent with age, and following experimentally induced muscle injury, treated aged mice showed a 1.8-fold increase in cross-sectional muscle fiber area during regeneration compared to untreated aged mice. This is a genuinely distinct application from the obesity data above, aimed at age-related muscle stem cell dysfunction rather than fat mass, and it's the same NAD+/SAM mechanism applied to a different tissue.
Mouse Study (Aged Animals, Muscle Injury Model) · Endpoint: Muscle Stem Cell Proliferation and Regenerated Fiber Area, Not a Human OutcomeA 2024 Update: NNMT Inhibition Boosts Exercise Benefits in Aged Mice
Dimet-Wiley AL, Latham CM, Brightwell CR, et al. "Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice." Scientific Reports. 2024;14(1):15554. doi: 10.1038/s41598-024-66034-9. PMID: 38969654. This more recent study treated 22-month-old (aged) female mice with 5-Amino-1MQ (10 mg/kg subcutaneously) for 8 weeks, with or without a concurrent exercise program. The drug alone increased grip strength by about 25%, roughly matching the effect of exercise alone. Combining the drug with exercise produced about a 60% increase in grip strength, and exercised mice on the drug showed roughly a 150% increase in daily running distance compared to exercise-only controls, whose running distance improvement tapered off over the study. This is the newest data on the compound and the first to frame it as something that can mimic or amplify exercise-driven adaptations in aged muscle, not just a fat-loss agent.
Mouse Study (Aged Animals, 8-Week Treatment ± Exercise) · Endpoint: Grip Strength and Voluntary Running Distance, Not a Human OutcomeA 2025-2026 Update: The First Look at 5-Amino-1MQ in Human Cells, in Kidney Aging and Fibrosis
Chanvillard L, Lantermans H, Wall C, et al. "NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease." Cell Reports. 2026. PMID: 41543936. (Posted as a preprint in January 2025, doi: 10.1101/2025.01.06.631437.) This is the most significant addition to the evidence base since this guide was first written, and it's the first time 5-Amino-1MQ's protective effect has been shown outside of mice. Using kidney organoids grown from stem cells donated by actual chronic kidney disease patients, primary human kidney tubule cells, and kidney biopsy tissue from people with diabetic kidney disease, the researchers found that NNMT rises specifically in the aging, senescent tubule cells that drive kidney fibrosis, and that treating those human cells with 5-Amino-1MQ reduced markers of cellular senescence (p21 expression, SA-β-gal activity), restored a healthier SAM/SAH methylation balance, reduced fibrosis-driving proteins (α-SMA and other EMT markers), and let stressed cells resume proliferating instead of accumulating as senescent cells, roughly a 70% increase in proliferation under stress conditions in one experiment. The same protective pattern held up separately in diabetic mice and in a mouse model of kidney scarring (unilateral ureteral obstruction). Kidney tubular aging is a different organ system entirely from the fat and muscle findings above, and finding the same NAD+/SAM mechanism doing the same protective job in a third, unrelated tissue, this time in real human cells and not only mice, is a genuinely encouraging sign that this is a broader anti-aging mechanism worth pursuing, not a fat-cell curiosity. It is still not a clinical trial of the drug in a living person, and a single study needs independent replication before it should change anything for a patient, but the case for running that human trial just got measurably stronger.
Human Kidney Organoids, Primary Human Tubule Cells, and Human CKD Biopsy Tissue, plus Diabetic Mice and a Mouse Fibrosis Model · Endpoint: Cellular Senescence Markers, Methylation Balance, and Fibrosis Markers, First Human Cell Data for This Compound, Not a Human Clinical TrialWhat the Research Doesn't Yet Show
Every quantitative result above still comes from mice, cell culture, or, in the newest case, human cells and tissue outside a living person. There are no completed or registered human trials of 5-Amino-1MQ, and a 2024 review of NNMT as a therapeutic target for metabolic syndrome states plainly that clinical trials of NNMT inhibitors, of any kind, haven't been documented. That gap matters for a few concrete reasons, not just as a disclaimer. The mouse dosing in the obesity study (roughly 34 mg/kg per day), the muscle-aging studies (10-20 mg/kg per day), and the kidney study (50 micromolar in cell culture) doesn't translate directly to a human dose; there is no published human pharmacokinetic data to make that conversion safely, and doses used in unregulated compounded products aren't derived from any human trial. The obesity data comes from 11 days of treatment and the muscle data from 8 weeks, both far short of the duration most patients would actually use a compound like this, and the kidney finding, while it includes human cells, is a single study that has not yet been independently replicated. The preclinical benefit also appears strongest in already-obese, insulin-resistant, or diseased tissue (diabetic kidneys, aged muscle), mirroring the human observational finding that NNMT overactivity concentrates in metabolic disease, which means the same effect size shouldn't be assumed in someone who is metabolically healthy already.
5-Amino-1MQ and direct NAD+ infusions are frequently discussed as interchangeable, but they work through different mechanisms: an NAD+ infusion supplies the molecule directly, while 5-Amino-1MQ is intended to preserve more of the nicotinamide your own cells already have available for NAD+ synthesis. Neither approach currently has controlled human trial data establishing a clinical outcome benefit. Blood NAD+ testing is commercially available, but there is no validated reference range connecting a specific blood NAD+ level to symptom improvement or treatment responsiveness, so a before-and-after NAD+ level is not, by itself, evidence that a patient benefited.
5-Amino-1MQ has no FDA approval for any indication and no established human dosing. If you're dealing with low energy, slower recovery, or brain fog, and wondering whether this is the answer, the more useful starting point is usually a broader look at your metabolic and hormone picture first. The mechanism behind this compound, and the fact that three independent tissue systems now show the same benefit from it, is a genuinely promising reason to want the human trial that hasn't been run yet; it isn't yet a reason to treat this compound as a proven answer for an individual patient today.
How This Fits the Cellular Medicine Framework
5-Amino-1MQ is best understood as an upstream lever on cellular energy metabolism rather than a signaling molecule: instead of activating a receptor the way a hormone or peptide does, it removes competition for a metabolic resource, nicotinamide, that multiple downstream processes depend on, NAD+-driven mitochondrial energy production and sirtuin activity among them. That makes it a genuinely interesting mechanism to watch, and also a clean illustration of why mechanism and human outcome are two different questions.
The pattern emerging across the evidence above, obesity and insulin resistance, aged skeletal muscle, and now kidney tubular aging and fibrosis, in human as well as mouse cells, is a genuinely encouraging one: three unrelated tissues, studied independently by different research groups, showing the same benefit from the same mechanism. That kind of convergence is exactly the sort of signal this framework treats as a real reason for optimism, and a real reason the next step should be a human trial of the compound itself, rather than a reason to assume the mouse and cell-culture data has already answered the question. Until that trial exists, this compound sits at the mechanism-and-preclinical-data stage of the framework, not the human-outcomes stage.
References
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. doi:10.1016/j.bcp.2017.11.007 · PMID: 29155147
- Kannt A, Pfenninger A, Teichert L, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015;58(4):799-808. doi:10.1007/s00125-014-3490-7
- Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019;163:481-492. doi:10.1016/j.bcp.2019.02.008 · PMID: 30753815
- Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep. 2024;14(1):15554. doi:10.1038/s41598-024-66034-9 · PMID: 38969654
- Sun WD, Zhu XJ, Li JJ, Mei YZ, Li WS, Li JH. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Front Pharmacol. 2024;15:1410479. doi:10.3389/fphar.2024.1410479
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. doi:10.1038/nature13198 · PMID: 24717514
- Chanvillard L, Lantermans H, Wall C, et al. NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease. Cell Rep. 2026. PMID: 41543936 (posted as a preprint doi:10.1101/2025.01.06.631437)
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.